Abstract
Drug combinations including irinotecan and gefitinib have been evaluated in clinical trials. SN-38 is the active metabolite of irinotecan, and the increase in its concentration due to drug interactions will result in increased clinical toxicity. We aimed to investigate the effects of gefitinib and its predominant metabolite observed in human plasma, O-desmethyl-gefitinib (DMG), on SN-38 glucuronidation. Our data indicated that both gefitinib and DMG are potent inhibitors of SN-38 glucuronidation via UGT1A1 inhibition. It is predicted from in vitro data that gefitinib administered at 700mg/day may result in about 149% increase in SN-38 AUC, but there is no significant effects on SN-38 AUC at lower concentrations. Our prediction study provides a basis for design of clinical studies for the development and optimization of this combination.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
